Navigation Links
BioNanomatrix Awarded Supplemental Funding to Accelerate Commercialization of Innovative Single-Molecule Analyzer

PHILADELPHIA, Oct. 15 /PRNewswire/ -- BioNanomatrix, Inc., a developer of breakthrough single-molecule genomic analysis technology, today announced receipt of two new supplemental grants totaling $833,490 from the National Human Genome Research Institute (NHGRI) of the U.S. National Institutes of Health (NIH). The funding is intended to support further commercial development of BioNanomatrix's nanoscale whole genome imaging and analysis platform. BioNanomatrix plans to use the funds to prepare for the upcoming beta site launch of its first commercial NanoAnalyzer® system, planned for the second quarter of 2010.

BioNanomatrix is applying its nanoscale technology to develop a unique platform that can rapidly and cost effectively analyze individual ultra-long strands of DNA in a massively parallel format. The benchtop system, currently in alpha evaluation, is designed to allow researchers to scan a human genome in as little as 10 minutes, creating an organizational map of each sample. Researchers at beta sites plan to evaluate the instrument for a wide range of applications, from genome integrity to structural variation mapping. Advanced applications, including epigenetic mapping and sequence analysis, will be added later in development.

"This new funding from NHGRI provides additional support as we ramp up for initiation of beta site testing of our first commercial NanoAnalyzer systems, planned for the second quarter of the new year," said Michael Boyce-Jacino, Ph.D., president and CEO of BioNanomatrix. "Our nanoscale technology is intended to allow researchers to directly image and analyze very long, individual intact strands of DNA at the single-molecule level, at high resolution and with very high throughputs, yielding a great deal of genomic information. We are, in essence, providing an imaging tool for genome analysis linking high-resolution sequence data with clinically important structural data in an easy-to-use and highly accessible way. We believe our technology has the potential to increase the utility of whole genome imaging and analysis for a wide range of research and diagnostic applications, and we are very pleased that NHGRI is continuing to support our progress towards commercialization."

These two new supplemental grants bring the total that BioNanomatrix has been awarded under the Phase II NHGRI grant program to more than $2.8 million. These grants are part of a Small Business Innovation Research (SBIR) program, awarded under the NIH BECON II nanotech initiative, an interdisciplinary, multi-institutes consortium. BioNanomatrix is also the co-recipient of an $8.8 million multi-year grant from the U.S. National Institute of Standards and Technology Advanced Technology Program (NIST-ATP) to develop a system capable of sequencing the human genome in eight hours at a cost of less than $100.

About BioNanomatrix

BioNanomatrix is developing breakthrough nanoscale whole genome imaging and analytic platforms for applications in biomedical research, genetic diagnostics and personalized medicine. The company's platform technology is designed to allow researchers to directly image and analyze very long, individual intact strands of DNA at the single-molecule level, at high resolution and with very high throughputs. This technology has the potential to increase the utility of whole genome imaging and analysis for a wide range of research and diagnostic applications, providing fast, comprehensive, and low-cost analysis of genomic, epigenomic and proteomic information. Its current development efforts include a NIST-ATP funded project to sequence the human genome at a cost of $100. The company also receives funding from the National Institutes of Health. BioNanomatrix's technologies are licensed exclusively from Princeton University. Founded in 2003, the company is headquartered in Philadelphia, Pennsylvania. For more information, visit:

    Barbara Lindheim
    GendeLLindheim BioCom Partners
    212 918-4650

SOURCE BioNanomatrix, Inc.

SOURCE BioNanomatrix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. BioNanomatrix Announces Issuance of Key Nanofluidics Patent Enabling Single Molecule Whole Genome Analysis
2. BioNanomatrix Receives New NCI Grant to Support Development of Chip-Based Nanofluidics Systems for Cell Fractionation
3. BioNanomatrix and Complete Genomics Receive $8.8 Million NIST-ATP Award to Develop Sequencing Platform for $100 Genome
4. BioNanomatrix Named Best Management Team at the 2008 Ben Franklin Emerging Business Awards
5. BioNanomatrix Announces Appointment of Paul R. Selvin to Its Scientific Advisory Board
6. BioNanomatrix Awarded New NIH Grant for Development of Nanoscale Platform for Single-Molecule DNA Mapping and Haplotype Applications
7. BioNanomatrix Announces Appointment of Dr. Pui-Yan Kwok to Its Scientific Advisory Board
8. BioNanomatrix Appoints Michael Kochersperger as Vice President of Engineering
9. BioNanomatrixs Revolutionary Whole Genome Analysis Platform Named to MIT Technology Reviews Annual 10 Emerging Technologies List
10. BioNanomatrix Appoints Genomic Research Experts Charles Lee and David L. Barker as Advisers
11. GeneNews CSO Dr. CC Liew awarded state honour by the Government of Malaysia
Post Your Comments:
(Date:11/26/2015)... CHESHAM , England , November 26, ... Lightpoint Medical, an innovative medical device company specializing in ... Euro grant from the European Commission as part of the ... enabling the company to carry out a large-scale clinical trial ... -->      (Logo: , ...
(Date:11/25/2015)... -- PharmAthene, Inc. (NYSE MKT: PIP) announced  today that its ... (Rights Plan) in an effort to preserve the value ... 382 of the Internal Revenue Code (Code). ... its NOLs could be substantially limited if the Company ... of the Code. In general, an ownership change occurs ...
(Date:11/25/2015)... Studies reveal the differences in species of ... way for more effective treatment for one of the most ... --> --> Gum disease is ... yet relatively little was understood about the bacteria associated with ... by researchers from the WALTHAM Centre for Pet Nutrition together ...
(Date:11/25/2015)... 2015  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) ... CEO of Neurocrine Biosciences, will be presenting at the ... New York . .   ... 5 minutes prior to the presentation to download or ... will be available on the website approximately one hour ...
Breaking Biology Technology:
(Date:11/12/2015)... 12, 2015  A golden retriever that stayed healthy ... (DMD) has provided a new lead for treating this ... Broad Institute of MIT and Harvard and the University ... Cell, pinpoints a protective gene ... disease,s effects. The Boston Children,s lab of Lou ...
(Date:11/11/2015)... MedNet Solutions , an innovative SaaS-based eClinical technology company that ... announce that it will be a Sponsor of the ... held November 17-19 in Hamburg , Germany.  ... iMedNet , MedNet,s easy-to-use, proven and affordable eClinical ... able to deliver time and cost savings of up to ...
(Date:11/9/2015)... DUBLIN , Nov. 09, 2015 /PRNewswire/ ... announced the addition of the "Global ... to their offering. --> ... "Global Law Enforcement Biometrics Market 2015-2019" ... Research and Markets ( ) ...
Breaking Biology News(10 mins):